Floatz logo

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells

Minimal Residual Disease

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Minimal Residual Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 2/3BB
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B
LIDOCAINE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B
Piritramide
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B

View all 50 →

Same molecule, other indications

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells is also rated in:

CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
Progressive DiseaseDormant
CCC
Indicative ·
48 / 100
View asset →
CD19 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →